Skip to main content

Table 1 Published studies on “CP7_E2alf” and their topics.

From: A decade of research into classical swine fever marker vaccine CP7_E2alf (Suvaxyn® CSF Marker): a review of vaccine properties

Topic Data covered by the article References
Vaccine design and construction Laboratory protocols for chimera design [40]
Construction of the chimera, sequence analysis, initial in vitro and in vivo tests [39]
Genetic stability Stability over cell culture passages, search for recombinants in co-infection studies, stability in vivo [18]
Safety Assessment of shedding through feces, urine and semen, dissemination [10]
Dissemination, onset of antibody responses, diagnostic tests [48]
Innocuousness and safety in target and non-target species [26]
Detection and dissemination of vaccine virus [24]
Efficacy Efficacy in the presence of MDA [15]
Efficacy in the presence of BVDV-1 antibodies, DIVA [11]
Efficacy in MDA negative piglets, intramuscular and oral vaccination with challenge at 14 dpv with CSFV “Koslov” [29]
Efficacy in piglets with MDA, intramuscular (3 weeks/6 weeks) and oral vaccination (6 weeks), challenge 14 dpv with CSFV “Koslov” [13]
Efficacy against different genotypes of CSFV, intramuscular and oral vaccination (domestic pigs and wild boar), challenge 14 dpv/21 dpv [6]
Efficacy after intramuscular vaccination and DIVA (comparative trial with different chimeras), challenge 7 and 14 dpv with CSFV “Koslov” [12]
Efficacy in piglets with C-strain derived MDA (5 weeks/8 weeks), challenge with CSFV “Koslov” 14 dpv [38]
Duration of immunity study, intramuscular and oral vaccination, challenge 6 months post vaccination with CSFV “Koslov” [17]
Efficacy after oral vaccination (comparative trial with different chimeras), challenge 14 and 21 dpv [4]
Onset of immunity and vaccine dose, efficacy study, genetic stability, intramuscular and oral vaccination [27, 28]
Efficacy (and safety) of oral immunization of wild boar [25]
DIVA diagnostics Development and validation of an Erns -specific double-antigen ELISA [34]
Design and evaluation of an Erns ELISA [33]
Evaluation of a discriminatory CSFV Erns ELISA in an inter-laboratory trial [37]
Differentiation of CSFV infection and “CP7_E2alf” vaccination using a multiplex microsphere immunoassay [53]
Design of two Erns antibody ELISAs [1]
Inter-laboratory comparison test of possible discriminatory assays [45]
Development of a RT-PCR system for vaccine/field virus discrimination (genetic DIVA) [31]
Development of a RT-PCR system for vaccine/field virus discrimination (genetic DIVA) [27]
Field study Oral vaccination of wild boar in faunistic hunting farms in Umbria, bait vaccination, comparative study in captive wild boar, vaccine stability [16]
Supplemental studies Kinetics of MDA upon intramuscular vaccination [44]
Cytokine and immunoglobulin isotype profiles [42]
Challenge 2 days after oral immunization, cytokine profiles [41]